View Financial HealthDermata Therapeutics 配当と自社株買い配当金 基準チェック /06Dermata Therapeutics配当金を支払った記録がありません。主要情報n/a配当利回り-220.8%バイバック利回り総株主利回り-220.8%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesDermata Therapeutics, Inc., Annual General Meeting, May 27, 2026Apr 09New major risk - Share price stability Jan 22New major risk - Financial position Jan 08New minor risk - Share price stability Sep 04Dermata Therapeutics, Inc. Announces Panel Grants Company’s Request for an Exception Until August 14, 2025Jul 08Dermata Therapeutics, Inc., Annual General Meeting, Jul 15, 2025May 26Dermata Therapeutics Regains Compliance with the Minimum Stockholders’ Equity Requirement and Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price RequirementMay 17New major risk - Financial position May 16Dermata Therapeutics, Inc. Announces Yymngari Phase 3 Star-1 Clinical Study DesignApr 16Dermata Therapeutics, Inc. Announces Positive Topline Results from First Pivotal Phase 3 Trial of YymngariMar 27Dermata Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity RequirementMar 26Dermata Therapeutics, Inc. Announces Last Patient Completes Last Visit in Pivotal Xymngari Phase 3 Star-1 Clinical Trial for AcneMar 04Dermata Therapeutics, Inc. announced that it has received $2.550008 million in fundingJan 23Dermata Therapeutics, Inc. Receives Approval from FDA for the Proprietary Name Xyngarifor for Its Phase 3 Clinical Drug Candidate in AcneDec 17Dermata Therapeutics, Inc. Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of AcneDec 12Dermata Therapeutics, Inc. Completes Enrollment in First Pivotal DMT310 Phase 3 Star-1 Clinical Trial for AcneDec 04New major risk - Financial position Nov 15Dermata Therapeutics, Inc. announced that it expects to receive $3.498089 million in fundingSep 18+ 1 more updateNew major risk - Financial position Aug 09Dermata Therapeutics, Inc. Announces Achievement of 50% Enrollment in Pivotal Dmt310 Phase 3 Star-1 Clinical Trial for AcneJul 18Dermata Therapeutics Regains Compliance with Listing Rule 5550(a)(4)May 25Dermata Therapeutics, Inc. Gets Nasdaq Extension to Regain ComplianceMay 16New major risk - Revenue and earnings growth Mar 27Dermata Therapeutics, Inc., Annual General Meeting, May 07, 2024Mar 27New major risk - Revenue and earnings growth Mar 23New major risk - Share price stability Jan 17Dermata Therapeutics, Inc. Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for AcneDec 21Dermata Therapeutics, Inc. to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 Based on Agreement with FDA on the Phase 3 ProtocolsNov 17+ 1 more updateNew major risk - Share price stability Nov 08New major risk - Financial position Aug 11Dermata Therapeutics, Inc. Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-To-Severe AcneJun 28Dermata Therapeutics, Inc., Annual General Meeting, Aug 03, 2023Jun 24Dermata Therapeutics, Inc. Announces Positive Results from its DMT310 Phase 2b Study of Its Once-Weekly Topical Treatment in Patients with Moderate-To-Severe Acne VivisJun 09Price target decreased by 96% to US$4.00 Apr 06Nasdaq Grants Dermata Therapeutics A 180-Day Extension to Regain Compliance with the Minimum Bid Price RequirementDec 17Dermata Therapeutics, Inc. Announces Topline Results from Its Phase 2 Trial of Once-Weekly Topical Application of DMT310 for the Treatment of Moderate-To-Severe RosaceaDec 06High number of new directors Nov 16Dermata Therapeutics Q2 GAAP EPS of -$0.24 Aug 15Dermata Therapeutics, Inc. Receives Written Notice from the Listing Qualifications Department of Nasdaq for Compliance with the $1.00 Minimum Bid Price RequirementJun 23Dermata Therapeutics, Inc., Annual General Meeting, Jul 11, 2022Jun 02High number of new directors Apr 27Dermata Therapeutics, Inc. Receives Correspondence from the U.S. Food and Drug Administration for Waiver Request for the Requirements to Complete a 90-Day Dermal ToxicityMar 04Dermata Therapeutics, Inc. Submits Requests to the U.S. Food and Drug Administration for the Waiver of the Requirements to Complete A 90-Day Dermal Minipig Study and a Standard Dermal Pharmacokinetic StudyFeb 06High number of new directors Jan 01We're Hopeful That Dermata Therapeutics (NASDAQ:DRMA) Will Use Its Cash WiselyNov 22Chief Financial Officer Thomas Insley has left the company Sep 03Dermata Therapeutics, Inc. has completed an IPO in the amount of $17.999996 million.Aug 14Less than half of directors are independent Aug 13決済の安定と成長配当データの取得安定した配当: DRMAの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: DRMAの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Dermata Therapeutics 配当利回り対市場DRMA 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (DRMA)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.6%アナリスト予想 (DRMA) (最長3年)n/a注目すべき配当: DRMAは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: DRMAは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: DRMAの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: DRMAが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/01 07:16終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Dermata Therapeutics, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Anthony VendettiMaxim Group
Dermata Therapeutics, Inc. Announces Panel Grants Company’s Request for an Exception Until August 14, 2025Jul 08
Dermata Therapeutics Regains Compliance with the Minimum Stockholders’ Equity Requirement and Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price RequirementMay 17
Dermata Therapeutics, Inc. Announces Positive Topline Results from First Pivotal Phase 3 Trial of YymngariMar 27
Dermata Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity RequirementMar 26
Dermata Therapeutics, Inc. Announces Last Patient Completes Last Visit in Pivotal Xymngari Phase 3 Star-1 Clinical Trial for AcneMar 04
Dermata Therapeutics, Inc. Receives Approval from FDA for the Proprietary Name Xyngarifor for Its Phase 3 Clinical Drug Candidate in AcneDec 17
Dermata Therapeutics, Inc. Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of AcneDec 12
Dermata Therapeutics, Inc. Completes Enrollment in First Pivotal DMT310 Phase 3 Star-1 Clinical Trial for AcneDec 04
Dermata Therapeutics, Inc. announced that it expects to receive $3.498089 million in fundingSep 18+ 1 more update
Dermata Therapeutics, Inc. Announces Achievement of 50% Enrollment in Pivotal Dmt310 Phase 3 Star-1 Clinical Trial for AcneJul 18
Dermata Therapeutics, Inc. Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for AcneDec 21
Dermata Therapeutics, Inc. to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 Based on Agreement with FDA on the Phase 3 ProtocolsNov 17+ 1 more update
Dermata Therapeutics, Inc. Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-To-Severe AcneJun 28
Dermata Therapeutics, Inc. Announces Positive Results from its DMT310 Phase 2b Study of Its Once-Weekly Topical Treatment in Patients with Moderate-To-Severe Acne VivisJun 09
Nasdaq Grants Dermata Therapeutics A 180-Day Extension to Regain Compliance with the Minimum Bid Price RequirementDec 17
Dermata Therapeutics, Inc. Announces Topline Results from Its Phase 2 Trial of Once-Weekly Topical Application of DMT310 for the Treatment of Moderate-To-Severe RosaceaDec 06
Dermata Therapeutics, Inc. Receives Written Notice from the Listing Qualifications Department of Nasdaq for Compliance with the $1.00 Minimum Bid Price RequirementJun 23
Dermata Therapeutics, Inc. Receives Correspondence from the U.S. Food and Drug Administration for Waiver Request for the Requirements to Complete a 90-Day Dermal ToxicityMar 04
Dermata Therapeutics, Inc. Submits Requests to the U.S. Food and Drug Administration for the Waiver of the Requirements to Complete A 90-Day Dermal Minipig Study and a Standard Dermal Pharmacokinetic StudyFeb 06
